We are Sorry, This Page doesn't Exist
Capitalizing On Crypto: Riot And Iris Energy Present Opportunities, Analyst Sees 100% Upside
JPMorgan analyst Reginald L. Smith rates RIOT and IREN stocks as Overweight; With IREN, the stock offers 100% upside potential. Latest Ratings for RIOT DateFirmActionFromTo Mar .....»»
Why Needham Likes Cloud Stock Anaplan In 2021
Cloud-based software stocks have done well amid the work-from-home and study-from-home environment necessitated by the COVID-19 pandemic in 2020. Despite the pricier valuation of the category, an analyst at Needham picked one of the stocks as a recove.....»»
NC drugmaker sees $82 million in federal funding for Covid-19 treatment
A Triangle drug company on the verge of a commercial launch is also bringing in big money to study its potential coronavirus treatment......»»
MacroGenics Analyst Sees Multiple Sources Of Upside, Biopharma Rallies After Q1 Update
MacroGenics Inc (NASDAQ: MGNX) reported Tuesday after the close with forecast-beating first-quarter results and sa.....»»
MacroGenics Analyst Sees Multiple Sources Of Upside, Biopharma Rallies After Q1 Update
MacroGenics Inc (NASDAQ: MGNX) reported Tuesday after the close with forecast-beating first-quarter results and said it has adequate cash to operate into 2022. La.....»»
Morgan Stanley sees Gilead up 5%-10% on NIAID COVID-19 study meeting endpoint
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Gilead Analyst Sees Catalyst Ahead In Data Readout For Potential Coronavirus Treatment
Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir is one of the frontrunners among investigational drugs to treat COVID-19. Latest.....»»
Citi still sees "significant upside" in Cigna despite COVID-19 concerns
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
More reasons to buy stocks than sell -analyst
Wayne Kauffman, chief market analyst at Phoenix Financial Services, believes the U.S. stock market is still relatively cheap and sees another 6 to 9 percent upside in the S&P 500 by year's end. Conway G. Gittens reports......»»
Why One Analyst Sees Sarepta’s Roche Deal Taking Off
Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this........»»
Why One Analyst Still Sees Almost 200% Upside in Paratek Pharma, Even After Its Huge Gain
This Wedbush analyst sees close to 200% in potential upside in Paratek Pharmaceuticals beyond the massive one-day gain on Thursday......»»
Why Wedbush Sees More Upside in Nike Ahead of Earnings
Nike has been an outstanding Dow component so far in 2019, despite its exposure to China. Even though trade talks are ongoing and nothing has been fully resolved yet, one analyst sees Nike’s........»»
One Analyst Sees Strong 2020 for McDonald’s, Starbucks, Domino’s and Darden
RBC Capital Markets has taken a renewed look at the restaurant industry, and the firm sees some serious upside for some major names within the industry......»»
After a 50% Drop, One Analyst Sees Bluebird Bio With Almost 50% Upside
On a day that the Dow Jones industrials and S&P 500 just hit all-time highs, many companies are not exactly feeling the same love. Bluebird Bio is one such company......»»
Why Credit Suisse Sees Over 35% Upside at Amazon
Amazon will be releasing its third quarter results later this month and one key analyst weighed in on the e-commerce empire ahead of these results......»»
Despite the Big Move in Gold Prices, RBC Still Sees Upside to Top Stocks
An analyst's report makes the case that the top gold mining and royalty stocks have lagged the big move in the actual spot price of gold. These three stocks still offer investors solid upside........»»
Analyst Sees Big Upside in Nuance Communications After the Spin-Off
Nuance Communications is planning to spin off its auto business into a new public company, Cerence, which will begin trading on October 1. Ahead of this spin-off, Wedbush met with executives to........»»
Even More Implied Analyst Upside for Karyopharm Therapeutics After Royalty Pact
Karyopharm rose sharply on news of a royalty agreement that could bring as much as $150 million in new capital to the company, and one analyst sees much higher upside on the heels of the news......»»
Why This Analyst Sees Massive Upside for Restaurant Brands International
Restaurant Brands International has enjoyed a prosperous 2019, and Argus now has initiated coverage on the shares......»»